PT  - JOURNAL ARTICLE
AU  - Parent, Ephraim E.
AU  - Schuster, David M.
TI  - Update on <sup>18</sup>F-Fluciclovine PET for Prostate Cancer Imaging
AID  - 10.2967/jnumed.117.204032
DP  - 2018 May 01
TA  - Journal of Nuclear Medicine
PG  - 733--739
VI  - 59
IP  - 5
4099  - http://jnm.snmjournals.org/content/59/5/733.short
4100  - http://jnm.snmjournals.org/content/59/5/733.full
SO  - J Nucl Med2018 May 01; 59
AB  - PET is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic acid (18F-fluciclovine) is a nonnaturally occurring amino acid PET radiotracer that was recently approved by the U.S. Food and Drug Administration for detection of suspected recurrent prostate cancer. The tumor-imaging features of this radiotracer mirror the upregulation of transmembrane amino acid transport that occurs in prostate cancer because of increased amino acid metabolism for energy and protein synthesis. This continuing medical education article provides an overview on 18F-fluciclovine PET diagnostic capabilities for primary and metastatic disease, including reviews of published comparisons to conventional imaging and other molecular imaging agents. Additionally, the imaging procedure and image interpretation are detailed, including physiologic and pathologic uptake patterns and pitfalls.